PeptideFactSheetsAn independent reference
Menu

Selective estrogen-receptor modulator · Fact sheet

Enclomiphene

Also known as Enclomifene · Androxal · EnCyzix

Enclomiphene is an estrogen-receptor modulator studied in men with secondary hypogonadism. Trials raised testosterone and preserved sperm concentrations, but those measures do not establish symptom relief, live-birth benefit or FDA approval.

Not FDA approvedModerate human evidence
Hormones & sexual health

What is Enclomiphene?

Enclomiphene is one component of clomiphene, which contains two isomers. An enclomiphene-only product is a different medicine.

It is a SERM, not a SARM, peptide or approved form of testosterone replacement.

Benefits & claims

Interest includes performance or metabolic effects, but a mechanism, hormone change or lean-mass result does not establish safe improvement in athletic function.

What the evidence supports

  • Enclomiphene increased testosterone and gonadotropins in selected men with secondary hypogonadism.
  • Sperm concentration was maintained compared with suppression seen during topical testosterone treatment.
  • Hormone normalization and sperm counts do not demonstrate symptom improvement or fertility outcomes.
Research areas
  • Secondary hypogonadism
  • Testosterone and gonadotropin measures
  • Sperm concentration

Dosage & frequency

Human study context

This is an exposure from a named human study, not a generally established treatment or enhancement regimen.

How to read these amounts

An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.

Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences

Formulations, interactions & practical context

Formulation differences

  • It is a SERM, not a SARM, peptide or approved form of testosterone replacement.

Interactions & precautions

  • The reviewed sources do not establish a comprehensive human interaction profile for this exact substance or combination.

What is still unresolved

  • Long-term clinically meaningful benefit
  • Endocrine, cardiovascular and organ safety
  • Identity, exposure and interaction differences outside research settings
Testosterone Restoration by Enclomiphene Citrate in Men with Secondary Hypogonadism: Pharmacodynamics and Pharmacokinetics. Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone: restoration instead of replacement. EMA: EnCyzix assessment and refusal

Side effects & risks

  • Regulatory review identified unresolved benefit-risk questions, including thromboembolic concern.
  • Long-term cardiovascular, visual, reproductive and other adverse effects require direct assessment; isolated-isomer products cannot inherit all evidence for clomiphene mixtures.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research

Moderate human evidence

Randomized trials measured testosterone, gonadotropins and sperm counts. EMA refused EnCyzix authorization because adequate clinical benefit was not established in the proposed setting.

Studies

Personal experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.

No attributable personal accounts were found in the sources reviewed.

Approval status

Enclomiphene has no FDA-approved therapeutic product. The cited research does not establish an approved performance-enhancement use.

Phase 3 research; no FDA-approved product

Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.

Open questions

  • Long-term clinically meaningful benefit
  • Endocrine, cardiovascular and organ safety
  • Identity, exposure and interaction differences outside research settings

Summary

Hormone normalization and sperm counts do not demonstrate symptom improvement or fertility outcomes.

Sources

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

  3. medical institutionEMA: EnCyzix assessment and refusal

    Primary regulator record; testosterone changes did not establish adequate clinical benefit and safety for authorization.

How we assess sources · Suggest a correction